Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, Court BV, Milner D, Raben D, Woessner R, Heasley L, Nemenoff R, Clambey E, Karam SD. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer. J Natl Cancer Inst. 2019 Dec 1;111(12):1339-1349. PubMed PMID: 30863843
Zhai L, Ladomersky E, Lauing KL, Wu M, Scholtens DM, Savoor R, Zhang B, Wu JD, Horbinski C, Lukas RV, Binder DC, Wainwright DA. Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al . (2017). Oncoimmunology. 2019;8(3):1548242. PubMed PMID: 30723577
Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, Kim HM, Raben D, Tan AC, Heasley L, Clambey E, Nemenoff R, Karam SD. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin Cancer Res. 2018 Nov 1;24(21):5368-5380. PubMed PMID: 30042205
Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, Gritsina G, Sun X, Liu Y, Yu F, Gong W, Liu Y, Jiang B, Tang T, Patel R, Platanias LC, James CD, Stupp R, Lukas RV, Binder DC, Wainwright DA. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018 Jun 1;24(11):2559-2573. PubMed PMID: 29500275
Binder DC, Ladomersky E, Lenzen A, Zhai L, Lauing KL, Otto-Meyer SD, Lukas RV, Wainwright DA. Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma. Transl Cancer Res. 2018 Apr;7(Suppl 4):S510-S513. PubMed PMID: 30283731
Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Gyorffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. PubMed PMID: 28751450
Zhai L, Ladomersky E, Dostal CR, Lauing KL, Swoap K, Billingham LK, Gritsina G, Wu M, McCusker RH, Binder DC, Wainwright DA. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immun. 2017 May;62:24-29. PubMed PMID: 28179106
Binder DC, Wainwright DA. The Boosting Potential of Bacteria in Cancer Immunotherapy. Trends Mol Med. 2017 Jul;23(7):580-582. PubMed PMID: 28583420
Stokes WA, Binder DC, Jones BL, Oweida AJ, Liu AK, Rusthoven CG, Karam SD. Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy. J Neuroimmunol. 2017 Dec 15;313:118-122. PubMed PMID: 29153603
Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J, Graham C, Binder D, Serkova N, Raben D, Heasley L, Clambey E, Nemenoff R, Karam SD. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology. 2017;6(10):e1356153. PubMed PMID: 29123967
Binder DC, Arina A, Wen F, Tu T, Zhao M, Hoffman RM, Wainwright DA, Schreiber H. Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium. Oncoimmunology. 2016 Jun;5(6):e1130207. PubMed PMID: 27471609
Binder DC, Davis AA, Wainwright DA. Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology. 2016 Feb;5(2):e1082027. PubMed PMID: 27057463
Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing KL, Lulla RR, Fangusaro J, Lenzen A, Kumthekar P, Raizer JJ, Binder DC, James CD, Wainwright DA. Improving vaccine efficacy against malignant glioma. Oncoimmunology. 2016 Aug;5(8):e1196311. PubMed PMID: 27622066
Binder DC, Fu YX, Weichselbaum RR. Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends Mol Med. 2015 Aug;21(8):463-5. PubMed PMID: 26091823
Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, Wainwright DA. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res. 2015 Dec 15;21(24):5427-33. PubMed PMID: 26519060
Mustafi D, Gleber SC, Ward J, Dougherty U, Zamora M, Markiewicz E, Binder DC, Antic T, Vogt S, Karczmar GS, Oto A. IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model. AJR Am J Roentgenol. 2015 Sep;205(3):W313-9. PubMed PMID: 26295667
Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber H. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res. 2013 Aug;1(2):123-33. PubMed PMID: 24455752
Binder DC, Schreiber H. High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies. Oncoimmunology. 2013 Dec 1;2(12):e26704. PubMed PMID: 24563823
Clinical Interests
I have a particular interest in gastrointestinal, breast, prostate, and gynecologic malignancies.
My specialization includes the most advanced treatment techniques including high dose rate brachytherapy, prostate procedures, stereotactic body radiotherapy, and gamma knife.
Care Philosophy
I value being a member of a multidisciplinary team of cancer physicians that individualize the best treatment option for each patient, while then executing care using the most up-to-date technology. I treat each patient with respect and work with them to define a treatment approach that best aligns with their goals and values. My mission is to eradicate tumors while helping patients maintain their lifestyle during and following treatment.
General Information
Medical Schools:
MD, University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
(2015)
Graduate Schools:
PhD, University of Chicago
(2013)
Undergraduate Schools:
BA, Cornell University (NY)
(2007)
Internships:
University of Chicago/University of Illinois College of Medicine at Chicago Program
(2016)
Residency Programs:
University of Colorado, Chief Resident, Radiation Oncology (2020)